3C
ANIK icon

361 Capital’s Anika Therapeutics ANIK Stock Holding History

361 Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-23,509
Closed -$1.22M – 291
2019
Q4 		$1.22M Sell
23,509
-26,015
-53% -$1.51M 0.34% 165
2019
Q3 		$2.72M Sell
49,524
-15,497
-24% -$796K 0.5% 53
2019
Q2 		$2.64M Buy
+65,021
New +$2.37M 0.47% 90

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

361 Capital's ANIK Position: Q1 2020 in Review

361 Capital sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 23,509 shares — an estimated $1.22M sold.

361 Capital first reported a position in ANIK in Q2 2019 and held it in 3 quarters. The position peaked at $2.72M in Q3 2019. 164 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • 361 Capital reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • 361 Capital sold 23,509 Anika Therapeutics shares in Q1 2020, an estimated $1.22M.
  • 361 Capital first reported a position in Anika Therapeutics in Q2 2019 and held it in 3 quarters.
  • 361 Capital's Anika Therapeutics position peaked at $2.72M in Q3 2019.
  • 164 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.